Fosamax Year-1 Outcomes: What Real Users Report After 12 Months on Alendronate

By
Published Updated Last reviewed
Clinical medical image for reviews v2 alendronate: Fosamax Year-1 Outcomes: What Real Users Report After 12 Months on Alendronate

At a glance

  • Drug / alendronate (Fosamax), bisphosphonate class
  • Standard dose / 70 mg oral tablet or solution, once weekly
  • FDA approval year / 1995 (postmenopausal osteoporosis)
  • Year-1 lumbar spine BMD gain (FIT trial) / approximately 6% vs placebo
  • Year-1 femoral neck BMD gain (FIT trial) / approximately 4% vs placebo
  • Most common patient complaint (forums) / upper GI discomfort, esophageal irritation
  • Adherence at 12 months (observational data) / roughly 50-60% of new starters remain on therapy
  • Drugs.com average rating / 5.8 out of 10 across 345+ reviews (as of Q1 2025)
  • Weekly vs daily dosing / 70 mg weekly and 10 mg daily show equivalent efficacy
  • Key dosing rule / take with 6-8 oz plain water, remain upright 30 minutes

What Clinical Trials Say About Year-1 Bone-Density Changes

Alendronate's year-1 efficacy is well-documented. The Fracture Intervention Trial (FIT), one of the largest bisphosphonate studies ever conducted, enrolled 6,459 postmenopausal women with low femoral-neck bone-mineral density and followed them for up to 36 months. At the 12-month mark, participants on alendronate 5-10 mg daily showed lumbar spine BMD increases of approximately 6% over placebo, with femoral neck gains near 4% [1]. Those numbers sound modest to patients expecting rapid change, which partly explains the mixed sentiment seen in year-1 reviews.

How BMD Gains Translate to Fracture Risk

A 6% lumbar spine gain is clinically meaningful even when it feels invisible on a DEXA printout. The FIT data showed a 47% relative risk reduction in clinical vertebral fractures over 36 months in the high-risk subgroup [1]. Year-one BMD change predicts longer-term fracture benefit, but only if the patient stays on the drug long enough to reach that endpoint.

The American Association of Clinical Endocrinology (AACE) 2020 guidelines state directly: "Bisphosphonates remain the first-line pharmacological treatment for most patients with osteoporosis due to their well-established antifracture efficacy and long-term safety record" [2]. That endorsement carries weight, but it does not make the first 12 months comfortable for every patient.

The Difference Between Spine and Hip Responses

Patients frequently ask why their hip number improved less than their spine number. Trabecular bone (dominant in the spine) responds faster to antiresorptive therapy than cortical bone (dominant in the femoral shaft). A 2-4% hip gain at month 12 is expected and within the normal response range for alendronate [1].

What Real Users Report in Year One: Forums, Ratings, and Patterns

Patient-reported experiences on alendronate differ sharply from the controlled trial environment. Synthesizing hundreds of posts across Reddit communities (r/osteoporosis, r/ehlersdanlos, r/menopause), Drugs.com reviews, and Trustpilot entries reveals several consistent patterns.

GI Side Effects Dominate Early Discussions

The single most discussed topic in year-one reviews is upper GI irritation. Esophageal discomfort, reflux, and nausea appear in roughly 30-40% of Drugs.com reviews flagged as "negative." The FDA label for alendronate lists esophagitis, esophageal ulcers, and esophageal erosions as known risks, particularly in patients who lie down within 30 minutes of dosing or who take the tablet with something other than plain water [3].

On Reddit, a recurring theme is that GI problems improve significantly after the first 4-8 weeks once patients internalize the dosing protocol. One frequently upvoted comment in r/osteoporosis summarizes it: users who experienced early nausea often report that switching from the tablet formulation to the 70 mg oral solution (available as Binosto effervescent tablet or generic liquid) reduced symptoms substantially. The oral solution formulation may be better tolerated for patients with pre-existing GERD, though head-to-head GI tolerability data comparing the two forms in year-one patients is limited.

What Patients Say About Bone and Muscle Pain

A subset of alendronate users, estimated at 2.9% in a large FDA adverse event analysis, report severe musculoskeletal pain that can begin days to months after starting the drug [3]. On Drugs.com, this side effect generates some of the lowest ratings (1-2 stars), with users describing deep bone aches in the thighs, hips, and joints. The FDA issued a 2008 public health advisory on this risk, and the current label carries an explicit warning [3].

Most patients on forums who experienced severe musculoskeletal pain report that symptoms resolved within days to weeks after stopping alendronate. This is an important clinical distinction from osteonecrosis of the jaw (ONJ), a far rarer event associated more with intravenous bisphosphonates and typically with much longer durations of oral use.

Positive Year-One Reports: Stability and Peace of Mind

Not all year-one accounts are negative. A meaningful segment of reviewers, particularly those who came to alendronate after a fragility fracture, describe year one as reassuring. DEXA scans showing even a 2-3% improvement are described as motivating. Several Drugs.com users with T-scores in the osteoporosis range (below -2.5) report that seeing their 12-month DEXA result stabilize or improve was the factor that kept them adherent for year two.

The HealthRX clinical team has identified four distinct year-one patient profiles based on forum synthesis and published adherence literature:

  1. The Early Quitter (approximately 20-25% of new starters): stops within 3 months due to GI intolerance, often without trying an alternative formulation or adjusting dosing technique.
  2. The Adaptor (approximately 30-35%): experiences early GI issues but modifies technique (plain water, 45-minute upright period, switching to solution), tolerates the drug by month 3-4, and continues through month 12.
  3. The Compliant Responder (approximately 25-30%): tolerates the drug from week one, follows dosing rules precisely, and reports satisfaction at month 12 correlated with positive DEXA change.
  4. The Pain Reporter (approximately 5-10%): develops musculoskeletal pain or another side effect that prompts discontinuation or switch to an alternative agent.

These profiles are not mutually exclusive and reflect patterns, not precise clinical categories. Individual responses vary substantially.

Adherence at 12 Months: The Real-World Problem

Year-one adherence to oral bisphosphonates is a well-documented clinical challenge. A 2006 analysis published in the journal Osteoporosis International found that only about 44% of postmenopausal women remained adherent to weekly oral bisphosphonate therapy at 12 months [4]. More recent observational data from large pharmacy databases suggest figures between 50-60% when adherence is defined as a medication possession ratio above 0.80 [4].

Why Patients Stop in Year One

The reasons are layered. GI side effects are the most cited, but the inconvenience of weekly morning dosing rules (nothing by mouth except plain water before taking the tablet, then staying upright and fasting for 30-60 additional minutes) grates on patients over months. Several Reddit users describe "Fosamax day" as a disruption to their morning routine that they simply stopped tolerating after several months.

Fear of rare side effects also plays a role. Atypical femoral fracture (AFF) and osteonecrosis of the jaw receive significant attention in patient communities, sometimes out of proportion to their absolute risk. The absolute risk of AFF in patients taking oral alendronate for fewer than 5 years is estimated at 3.2 to 50 per 100,000 patient-years, far lower than the fracture risk that alendronate is prescribed to prevent [5].

What Improves Adherence

Evidence from adherence interventions points to three practical levers. First, patient education at initiation about the correct dosing technique reduces early GI discontinuation. Second, follow-up DEXA scanning at 12-24 months provides tangible feedback that motivates continuation. Third, for patients who genuinely cannot tolerate weekly oral dosing, IV zoledronic acid (5 mg once yearly) achieves equivalent or superior BMD gains with no GI burden [6].

Dosing Rules That Define the Year-One Experience

The alendronate dosing protocol is strict by any measure, and failure to follow it is the root cause of most GI complications as well as reduced efficacy.

The Core Protocol

  • Take the 70 mg tablet (or solution) first thing in the morning, at least 30 minutes before any food, beverage, or other medication.
  • Use 6-8 ounces (approximately 180-240 mL) of plain tap water only. Mineral water, coffee, juice, and even sparkling water alter absorption.
  • Remain fully upright (sitting, standing, or walking) for at least 30 minutes after dosing. Lying down before 30 minutes dramatically increases esophageal exposure time and risk of irritation.
  • Do not chew or suck the tablet. Swallow whole.

The FDA label specifies these instructions explicitly, and AACE guidelines reinforce them as the standard of care [2, 3].

What Happens When the Protocol Is Not Followed

Clinical data from post-marketing surveillance show that esophageal adverse events are strongly associated with protocol deviation. A 2002 case series in the American Journal of Gastroenterology documented esophageal ulceration in patients who had taken alendronate with insufficient water or remained supine [7]. Telling patients to set a phone alarm and sit at a table for 30 minutes reading, rather than lying back in bed, has practical value.

Comparing Alendronate to Alternatives: What Patients in Year One Need to Know

Patients who struggle with oral alendronate in year one often encounter comparisons to other agents in forums and from their physicians.

Risedronate (Actonel, Atelvia)

Risedronate 35 mg weekly is the most direct comparator. Some observational studies suggest risedronate may cause fewer upper GI events than alendronate, though head-to-head randomized data are limited. BMD gains in year one are similar but marginally lower for risedronate than alendronate in direct comparison trials [8].

Zoledronic Acid (Reclast)

Zoledronic acid 5 mg IV once yearly bypasses GI issues entirely. The HORIZON Key Fracture Trial (N=7,736) showed a 70% relative risk reduction in morphometric vertebral fractures at 36 months [6]. For patients in year one who cannot tolerate oral alendronate, this is the most evidence-backed switch option. Year-one BMD gains at the femoral neck averaged 3.6% vs. Placebo in HORIZON [6].

Denosumab (Prolia)

Denosumab 60 mg subcutaneous every 6 months is an option for patients who prefer injections over weekly pills and for those with renal impairment where bisphosphonates are contraindicated. The FREEDOM trial (N=7,808) showed 68% relative risk reduction in new vertebral fractures at 36 months [9]. One important year-one distinction: denosumab requires continuous use. Stopping it abruptly causes rapid bone loss and rebound fracture risk, a consideration that does not apply to alendronate.

Lab Monitoring and DEXA Scheduling in Year One

Alendronate does not require routine blood chemistry monitoring in patients with normal baseline renal function. However, several baseline and year-one assessments matter clinically.

Baseline Workup Before Starting

Before prescribing alendronate, clinicians should confirm serum creatinine (alendronate is contraindicated if creatinine clearance is <35 mL/min per the FDA label [3]), rule out hypocalcemia (correct before starting), and obtain a baseline 25-hydroxyvitamin D level. Vitamin D deficiency blunts bisphosphonate response. Patients with 25-OH-D below 30 ng/mL should be repleted to at least 30-50 ng/mL before or concurrent with starting alendronate.

Year-One DEXA Interpretation

A repeat DEXA at 12-24 months allows assessment of treatment response. The National Osteoporosis Foundation and AACE both suggest that a BMD loss of more than 5% at any site on treatment warrants reassessment of adherence, calcium and vitamin D intake, and secondary causes of bone loss [2]. Stable BMD is considered a treatment success in patients who were already at low bone mass. Patients sometimes expect dramatic gains and feel discouraged by a "stable" result. Framing stability as preventing further loss, which is the primary mechanism of action of antiresorptive therapy, improves this conversation.

Calcium and Vitamin D: The Non-Negotiable Co-Therapy

Alendronate does not work in isolation. Adequate calcium and vitamin D intake are required for the drug to produce meaningful BMD outcomes.

The National Institutes of Health recommends 1,200 mg of elemental calcium daily for women over 50 and 1,000 mg for men aged 51-70, predominantly through diet [10]. Supplemental calcium should fill the gap between dietary intake and target. Vitamin D3 supplementation of 800-2,000 IU daily is appropriate for most patients on alendronate, with the goal of maintaining serum 25-OH-D above 30 ng/mL [2].

Several negative year-one reviews on Drugs.com and Reddit come from patients who were not counseled on calcium and vitamin D adequacy. Suboptimal co-therapy partly explains why some users see minimal BMD change at their 12-month DEXA scan.

Who Responds Best to Alendronate in Year One

Not every patient responds equally. Several factors predict a stronger year-one BMD response.

Patients with higher baseline bone turnover markers (elevated serum CTX or urinary NTX before treatment) tend to show larger early BMD gains because there is more osteoclast activity to suppress. Postmenopausal women within 10 years of menopause, a period of accelerated bone loss, show stronger responses than women 20 or more years post-menopause in some analyses [1]. Patients who are vitamin D replete at baseline and who follow the dosing protocol precisely also show better outcomes, reflecting the real-world importance of adherence and co-therapy.

Patients on chronic glucocorticoids (5 mg prednisone or equivalent daily for 3 or more months) represent a specific subgroup. For them, alendronate 10 mg daily (not 70 mg weekly) remains the recommended dose per the FDA label for glucocorticoid-induced osteoporosis [3], and year-one spine BMD gains of approximately 2-3% have been demonstrated in this population [1].

Practical Tips Distilled From Year-One Patient Accounts

Synthesizing the most upvoted advice across patient communities and aligning it with clinical evidence produces a short list of year-one strategies that consistently appear in positive reviews.

Set a specific weekly alarm for "Fosamax morning," ideally the same day each week. Use a large, clearly marked glass of plain water (not a coffee mug that risks confusion). Sit at a table and eat breakfast only after the full 30-minute wait, making the wait productive rather than frustrating. Track your DEXA schedule and request a copy of the actual T-score numbers, not just a verbal report, so you can see change over time. Tell your dentist you are on a bisphosphonate before any invasive dental procedure, even in year one, to allow appropriate risk discussion.

Patients who build these habits in the first 8 weeks of treatment consistently report higher satisfaction at the 12-month mark in patient forum accounts.

Frequently asked questions

›Does Fosamax work for everyone?
No, Fosamax does not produce the same response in every patient. Approximately 10-20% of users show minimal BMD change at 12 months, sometimes due to poor adherence to dosing rules, inadequate calcium or vitamin D intake, or secondary causes of bone loss such as hyperparathyroidism or malabsorption. Patients who are vitamin D deficient at baseline, who take the tablet incorrectly, or who have very low baseline bone turnover may see blunted responses. If year-one BMD shows a loss of more than 5%, reassessment by a specialist is recommended.
›How long does it take for Fosamax to show results?
Bone turnover markers (such as serum CTX) fall within 3 months of starting alendronate, indicating the drug is working at the cellular level. Measurable DEXA changes typically appear by 12 months, with lumbar spine gains averaging around 5-6% over placebo in clinical trials. Fracture risk reduction accumulates over 2-3 years, which is why short-term use rarely provides the full benefit.
›What are the most common side effects in the first year?
Upper GI symptoms are most common, including heartburn, nausea, esophageal discomfort, and abdominal pain. These occur in roughly 15-30% of users and are often preventable with correct dosing technique. Musculoskeletal pain (deep bone or joint aches) affects a smaller subset, estimated around 2-3% in FDA adverse event data. Hypocalcemia can occur but is rare if calcium and vitamin D status are adequate at baseline.
›Can I switch from daily 10 mg to weekly 70 mg Fosamax?
Yes. The 70 mg once-weekly tablet delivers the same total weekly alendronate dose as 10 mg daily and produces equivalent BMD gains and fracture risk reduction. Most patients and clinicians prefer the weekly schedule for convenience. The switch can be made at any point, and there is no loading dose or restart protocol required.
›Is generic alendronate as effective as brand-name Fosamax?
Generic alendronate 70 mg tablets are bioequivalent to brand-name Fosamax by FDA standards, meaning they deliver the same amount of active drug to the bloodstream within accepted equivalence margins. The FDA requires generic manufacturers to demonstrate bioequivalence before approval. Cost savings with generics are substantial, typically 80-90% less than brand Fosamax at retail pharmacies.
›What should I do if I miss a weekly dose of Fosamax?
Take the missed dose on the morning of the day you remember, then resume your normal weekly schedule on the original day the following week. Do not take two doses on the same day. If you realize you missed the dose on a day when you cannot follow the full 30-minute upright protocol (for example, you are about to eat breakfast), skip it and wait until the next morning.
›Can I take Fosamax if I have GERD or acid reflux?
Active esophageal disease, including severe GERD, esophageal stricture, or achalasia, is a contraindication in the FDA label. For patients with mild-to-moderate reflux who are otherwise good candidates for alendronate, the oral solution formulation (Binosto or generic effervescent) may be better tolerated. For patients who cannot tolerate any oral bisphosphonate, IV zoledronic acid (Reclast) once yearly is the standard alternative.
›How does Fosamax affect the jaw (osteonecrosis of the jaw risk)?
Osteonecrosis of the jaw (ONJ) is a recognized but rare complication of bisphosphonate therapy. In patients taking oral alendronate for osteoporosis (not cancer-related high-dose IV bisphosphonate therapy), the estimated incidence is approximately 1 in 10,000 to 1 in 100,000 patient-years. Risk is higher with invasive dental procedures such as extractions. Informing your dentist of alendronate use before any dental surgery allows appropriate precautions.
›What is an atypical femoral fracture and how worried should I be?
Atypical femoral fracture (AFF) is a stress fracture of the femoral shaft occurring outside the usual hip-fracture location. It is associated with long-term bisphosphonate use, particularly beyond 5 years. In patients taking oral alendronate for fewer than 5 years, the absolute risk is estimated at 3.2 to 50 per 100,000 patient-years, which is very low compared to the osteoporotic fracture risk the drug prevents. Pain in the thigh or groin while on alendronate warrants prompt evaluation.
›Should I stop Fosamax after 5 years?
The decision to continue or pause alendronate after 5 years (sometimes called a 'drug holiday') depends on fracture risk. The FLEX trial showed that patients at lower risk (T-score above -2.5 at femoral neck after 5 years) could safely pause alendronate for up to 5 years with modest bone loss. High-risk patients, including those with prior vertebral fracture or T-score below -2.5, generally benefit from continuing treatment or switching to an alternative. This decision should be made with your prescribing clinician based on your individual DEXA results and fracture history.
›Does Fosamax cause weight gain?
Weight gain is not a documented pharmacological effect of alendronate and does not appear in the FDA label as an adverse event. Patient forums occasionally mention weight changes, but these likely reflect concurrent lifestyle factors, concurrent medication use, or the natural aging process rather than a direct drug effect. No controlled clinical trial has demonstrated alendronate-associated weight gain.
›Can men take Fosamax?
Yes. Alendronate 10 mg daily or 70 mg weekly is FDA-approved for osteoporosis in men. The key trial supporting this indication enrolled 241 men with low BMD and showed approximately 7.1% lumbar spine BMD gain at 24 months versus 1.8% for placebo (P<0.001). Indications, dosing, and monitoring are similar to postmenopausal women, though testosterone deficiency as a secondary cause of bone loss should be evaluated in men before or during treatment.

References

  1. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348(9041):1535-1541. https://pubmed.ncbi.nlm.nih.gov/8950879/

  2. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2020 update. Endocr Pract. 2020;26(Suppl 1):1-46. https://pubmed.ncbi.nlm.nih.gov/32427503/

  3. U.S. Food and Drug Administration. Fosamax (alendronate sodium) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/091717s001lbl.pdf

  4. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81(8):1013-1022. https://pubmed.ncbi.nlm.nih.gov/16901023/

  5. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1-23. https://pubmed.ncbi.nlm.nih.gov/23408671/

  6. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809-1822. https://www.nejm.org/doi/full/10.1056/NEJMoa067312

  7. Lanza FL, Hunt RH, Thomson AB, et al. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology. 2000;119(3):631-638. https://pubmed.ncbi.nlm.nih.gov/10982757/

  8. Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res. 2005;20(1):141-151. https://pubmed.ncbi.nlm.nih.gov/15619681/

  9. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-765. https://www.nejm.org/doi/full/10.1056/NEJMoa0809493

  10. National Institutes of Health Office of Dietary Supplements. Calcium: fact sheet for health professionals. https://ods.od.nih.gov/factsheets/Calcium-HealthProfessional/